Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris

Part of paid clinical trials in Albuquerque, New Mexico.

Sponsor
University of New Mexico
Study ID
NCT05030415
Phase
EARLY_PHASE1
Status
Completed

Conditions

  • Lichen Planopilaris
  • Lichen Planus
  • Lichen Planus Scalp

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the safety and efficacy of ixekizumab in lichen planus and lichen planopilaris clinical response by Total Body Surface (TBS) determination, Investigator Global Assessment (IGA) Score, Lichen Planopilaris Activity Index (LPPAI), and Frontal Fibrosing Alopecia Severity Score (FFASS).

Key Dates

Start date
Aug 12, 2021
Status verified
Mar 2024
Primary completion
Mar 25, 2024
Completion
Mar 25, 2024

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ixekizumab
    ixekizumab 80 mg injection, 160 mgs injected subcutaneously on week 0, 80 mgs injected subcutaneously every two weeks

Primary Outcome Measure

Investigator Global Assessment (IGA) [ Time Frame: 16 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of New MexicoAlbuquerqueNew Mexico87102-

Find similar trials in Albuquerque, NM

By research site
University of New Mexico· Albuquerque, NM

Related Studies